MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have ‘wide-ranging application’ as anti-inflammatory treatment. This is through the treatment’s modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body’s production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

‘We have long had confidence in CimetrA, and this latest study on its mechanism of action highlights even more potential applications for the product. This is a big leap forward, with more conditions potentially being able to be treated treatable with the drug,’ says Co-Founder & Managing Director Roby Zomer.

Current stock price: 0.97 pence, up 2.5% on Monday

12-month change: down 57%

Copyright 2022 Alliance News Limited. All Rights Reserved.